• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

GRAS Notices

  • Print
  • Share
  • E-mail
-

The inventory of GRAS notices provides information about GRAS notices filed since 1998, when FDA received its first GRAS notice. As of October 17, 2016, the GRAS final rule (81 FR 54960; August 17, 2016) requires a specific format for a GRAS notice. Prior to that date, FDA processed GRAS notices under the framework of the GRAS proposed rule (62 FR 18938; April 17, 1997). Notices received prior to the effective date of the GRAS final rule provide examples for potential notifiers for the types of information that may support a GRAS conclusion. In the inventory, notices follow the requirements for the format and content of a GRAS notice as of the effective date of the GRAS final rule.

The inventory notes what type of response letter the FDA sent in response to the notice. Notifiers often resubmit notices that FDA previously ceased to evaluate at the notifier’s request, and resubmitted notices commonly receive a letter indicating FDA has no questions, after addressing deficiencies. In the inventory, entries for notices that were later resubmitted link to the newer entry in the final column. Newer entries for notices that were resubmitted include a link to the previous submission below the substance name.

Some GRNs that FDA previously ceased to evaluate at the notifier’s request were later resubmitted as a food additive petition. For each of these cases, the GRN detail page links to the food additive petition.

After issuing a response letter, we may issue a subsequent letter as circumstances warrant. The issue dates of any subsequent letters are listed under the column, "Date of add’l correspondence.”

As of July 2025, FDA is posting notices in a Docket at www.regulations.gov. In these cases, the link for the notices will take you to the document posted at www.regulations.gov. We will update this information approximately monthly. More information about this inventory is available on the GRAS Notice Inventory Introduction page.


Search and display hints:

  • Select the specific GRN number below to view additional details about any GRAS Notice.
  • To sort by a specific field, click on the column header for that field.
  • To browse the records, use the Show All, First/Previous/Next/Last, and Jump To options at the bottom of the data table.
  • To search for a specific substance/term, enter the term in the Search box and select Show Items to display only those records that contain the selected term. (The search results also includes terms not shown on this page, but included in the full record on the detail page.)
  • The search results will return hits of records containing words that include the search term. For example, a search for the color red will return results that include terms such as reduce, ingredient, and cultured. To limit results to only the searched term, place a space before and after the word in the basic search or in the advanced search “this exact phrase” field.
Download GRAS Notices data in Microsoft Excel web format Download data from this searchable database in Excel format. If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Search within these results
Records Found: 17 Page 1 of 1
GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter Date of add'l correspondence Resubmitted as GRN No.
  1282
Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Jan 12, 2026 FDA has no questions (in PDF) (257 kB)
  1260
Rebaudioside M produced by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Nov 18, 2025 FDA has no questions (in PDF) (261 kB)
  1206
Rebaudioside M produced by enzymatic treatment of rebaudioside A purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Feb 28, 2025 FDA has no questions (in PDF) (253 kB)
  1203
Rebaudioside M2 obtained by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Bertoni Feb 12, 2025 FDA has no questions (in PDF) (191 kB)
  1184
Rebaudioside M from a modified strain of Escherichia coli BL21(DE3) Oct 23, 2024 FDA has no questions (in PDF) (245 kB)
  1010
Rebaudioside M obtained by enzymatic treatment of steviol glycosides purified from the leaves of Stevia rebaudiana (Bertoni) Jan 26, 2022 FDA has no questions (in PDF) (412 kB)
  882
Rebaudioside M
   (Resubmission of GRN 867)
Feb 2, 2020 FDA has no questions (in PDF) (479 kB)
  867
Rebaudioside M Sep 3, 2019 At the notifier's request, FDA ceased to evaluate this notice (in PDF) (36 kB)
  882
  846
Rebaudioside M Aug 23, 2019 FDA has no questions (in PDF) (102 kB)
  812
Rebaudioside M Dec 8, 2018 FDA has no questions (in PDF) (659 kB)
  799
Rebaudioside M Sep 25, 2018 FDA has no questions (in PDF) (112 kB)
  780
Rebaudioside M Jul 31, 2018 FDA has no questions (in PDF) (115 kB)
  759
Steviol glycosides consisting primarily of rebaudioside M produced in Yarrowia lipolytica May 25, 2018 FDA has no questions (in PDF) (106 kB)
  745
Steviol glycosides consisting primarily of rebaudioside M Apr 20, 2018 FDA has no questions (in PDF) (103 kB)
  744
Steviol glycosides consisting primarily of rebaudioside M Mar 23, 2018 FDA has no questions (in PDF) (131 kB)
  667
Rebaudioside M Feb 17, 2017 FDA has no questions (in PDF) (115 kB)
  512
High purity Rebaudioside M Oct 24, 2014 FDA has no questions

GRN No.
(sorted Z-A)
Substance Date of closure FDA's Letter Date of add'l correspondence Resubmitted as GRN No.
-
-